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Abstract 
The synthesis, physico-chemical, and biological characterisation of a short series of carnosine 
amides bearing NO-donor nitrooxy functionalities are described. The NO-donor carnosine 
analogues and their des-NO derivatives display carnosine-like properties, differing from the lead 
for their high serum stability. The newly-synthesised compounds are able to complex Cu2+ ions at 
physiological pH, displaying significant copper ion sequestering ability, and protect LDL from 
oxidation catalysed by Cu2+ ions. All products show moderately-potent HNE quenching activity. 
The NO donor compounds 7c-f relaxed rat aorta strips via a NO-dependent mechanism. In vivo 
evaluation of organ protection in a model of cerebral ischemia/reperfusion injury, using the 
selected NO-donor 7e and its des-NO analogue 7a, showed that both derivatives protect from 
hypoxiainduced brain damage, at lower concentrations than carnosine; 7e also decreased serum 
TNF-levels. This class of NO-donor carnosine amides is worthy of further study as potential 
tools for treating a wide range of chronic vascular and neurodegenerative diseases in which 
NObioavailability is reduced. 
 
Keywords: Carnosine; Carnosine amides; Cerebral Ischemia; Nitric Oxide; Nitrooxy Derivatives. 
 
1. Introduction 
Carnosine 1 is a histidine-containing dipeptide (β-alanyl-L-hystidine) (Chart 1) which in humans 
is principally present in muscle and nerve tissues [1]. It is rapidly cleaved into its constituents, in 
both cells and serum, under the action of carnosinases, a group of dipeptidases belonging to the 
family of metalloproteases [2]. At present, the physiological role of carnosine remains unclear. In 
vitro, it triggers a variety of biological actions [3]. In particular, it exerts protection against 
oxidative stress, being a scavenger of reactive oxygen (ROS) and nitrogen (RNS) species, which 
are responsible for oxidative damage of cellular lipids, enzymes, proteins and DNA [1,4-6]. In 
addition, carnosine can trap toxic electrophilic α,β- unsaturated aldehydes (e.g., (E) 4-hydroxy-
trans-2,3-nonenal (HNE) and malondialdehyde) deriving from the oxidation of unsaturated 
membrane lipids [7,8]. It protects proteins from glycation, thus inhibiting the formation of toxic 
advanced glycation end-products (AGEs) [8-10]. Since oxidative stress and AGEs are involved in 
the development and progression of some cardiovascular and neurodegenerative diseases [11,12], 
as well as in ageing, there is currently great interest in carnosine and its derivatives. Recently the 
effects of carnosine have been extensively studied both in vivo and in vitro in different models of 
oxidative driven damages, such as neurodegenerative disorders and hypoxia-ischemic injuries 
[13]. L-carnosine dietary supplementation proved able to promote a strong reduction in the 
hippocampal intraneuronal Aaccumulation, and to rescue AD and ageing-related mithocondrial 
disfunction in 3xTG-AD mice [14]. Unfortunately one limitation in employing L-carnosine as a 
protective drug is that it is rapidly inactivated by carnosinases. The chemical derivatization of 
carnosine is a very promising approach to realize therapeutic carnosinase-resistant molecules 
based on carnosine. The conjugation of carnosine with several types of organic molecules has the 
main purpose of reducing the carnosinase action on the peptide moiety, improving the 
multifunctional activity, because of the potential beneficial role of the conjugating moiety and the 
synergism with the peptide properties as well. 
Different modifications of the carnosine structure have been performed generating a number of 
multifunctional drug-like molecules which were recently reviewed [15,16]. Recent work on 
carnosine is directed toward the development of both D- and L-carnosine derivatives stable to 
carnosinase action. D-carnosine itself proved stable to carnosinase and superior to L-carnosine in 
some in vitro and in vivo pharmacological models [17,18]. The major drawback with D-carnosine 
lies in its low bioavailability, since it does not interact with hPEPT1, a transporter responsible for 
the uptake of a broad array of small peptides in the colon. This problem was addressed with the 
development of D-carnosine prodrugs; the octyl ester derivative was evaluated in vivo proving 
able to decrease hypertension, improve dislipidemia and restore renal function in Zucker fa/fa 
obese rats as well as to inhibit AGEs formation and oxidative stress [19]. 
Interestingly some new L-carnosine derivatives stable towards carnosinase action were recently 
synthesized by converting the carboxylic function to an amide and by conjugating the terminal 
primary amino group to a sugar substructure; these compounds showed carnosinase stability 
while retaining copper complexing ability [20]. 
Also our group has recently described some new L-carnosine amides bearing alkyl or arylalkyl 
substituent at the amide nitrogen endowed with different lipophilicities (chart 1, general structure 
I) [21]. These products share a number of properties with carnosine, including the ability to 
complex Cu2+ ions, to protect LDL from oxidation catalyzed by Cu2+, and HNE quenching 
activity. Further, in contrast to the lead, they also display high serum stability. 
NO is a pivotal signalling messenger in the cardiovascular system. Reduced NO bioavailability 
and abnormalities in NO-dependent signalling are among the central factors in vascular disease, 
and loss of endothelium-derived NO is known to be critical in the pathogenesis of vascular 
diseases, including hypertension, atherosclerosis, and vasospasm with compromised blood flow 
[22, 23]. 
Microvascular disorders, occurring with advanced age or in the presence of increased oxidative 
stress, are consequent on endothelial dysfunction, namely on a reduced capacity of endothelial 
cells to produce nitric oxide (NO) [24]. Furthermore, chronic mild long-lasting cerebrovascular 
dysfunction, involving basal NO deficit, significantly contributes to plaque development in 
Alzheimer's disease (AD) [23]. However, NO’s role in the brain is by no means fully elucidated, 
and both neuroprotective and neurotoxic effects have been widely reported and reviewed [25-27]. 
As a continuation of our work on NO-donor antioxidant drugs [28], this study aimed to synthesize 
and characterize new NO-donor carnosine derivatives, with high serum stability. New NO-donor 
compounds (Chart 1, derivatives 7c-f) were designed taking into account the relationship between 
clogD 7.4 and antioxidant activity we previously found (figure 1a); the determination of clogD 
values for these derivatives (7c = -3.12; 7d = -3.18, 7e = -3,19, 7f = -1,72) allowed us to 
anticipate their optimal hydrophilic-lipophilic balance in order to obtain potent antioxidant 
molecules. The NO-donor carnosine amides described were obtained by introducing one or two 
NO donor nitrooxy groups on the lateral chain of the amide nitrogen of scaffolds 7a,b. The 
introduction of two nitrooxy groups at the ω, ω-1 positions of the propyl chain of 7a afforded the 
two diastereoisomers 7d,e. 
The preliminary pharmacological profile of these products, its comparison with that of the related 
des-NO analogues 7a,b, including the results of an in vivo study of the protective effects of 7e 
and of 7a in a model of cerebral ischemia/reperfusion (I/R) injury, are also discussed. 
Insert Chart 1 
 
2. Results and discussion 
2.1. Chemistry 
The NO-donor carnosine amide structures, object of this study, were synthesized by the pathway 
depicted in Scheme 1. The commercially-available Nα-fluorenylmethoxycarbonyl-N-trityl- 
L-histidine (Fmoc-His(Trt)-OH) 2 was coupled with amines 3a,b or with the appropriate NO-
donor amines 3c-f, using the O-benzotriazol-1-yl-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate (HBTU)/1-hydroxybenzotriazole (HOBt)/di-isopropylethylamine (DIPEA) 
protocol, to give the corresponding intermediate amides 4a-f. Fmoc deprotection of these 
intermediates was carried out in DMF at room temperature in the presence of piperidine, to afford 
the amines 5a-f. Coupling of free amines with tert-butoxycarbonyl protected β-alanine (Boc-β-
Ala-OH) in the presence of dicyclohexylcarbodiimide (DCC) afforded 6a-f, and the subsequent 
simultaneous Trt/Boc deprotection using 10% (v/v) CF3COOH in CH2Cl2 furnished the target 
compounds 7a-f. 
 
Insert Scheme 1 
 
Intermediate substituted benzylamine 3b was synthesized by alkylation of commercially-available 
8, and the subsequent LiAlH4-mediated reduction of the cyano group. The amines bearing 
dinitrooxy functionalities 3d,e were synthesized by nitration with fuming nitric acid in CH2Cl2 
following the method reported elsewhere [29]. Compound 3f was obtained by reacting tosylate 11 
[30] with Boc-protected benzylaminophenol 12 [31] followed by CF3COOH-mediated 
deprotection (scheme 2). 
 
Insert Scheme 2 
 
2.2. Stability in human serum 
Two isoforms of carnosinase enzyme have been characterized thus far. The first is a cytosolic 
form (tissue carnosinase) while the second is present in the serum (serum carnosinase). It is not 
known why the enzyme is present in the serum. Although the neuroprotective effects of carnosine 
have been widely documented in the literature and recently confirmed by clinical studies in 
patients with stroke [32], widespread medical use of carnosine is limited by a high rate of its 
degradation in serum and tissues by carnosinase, which dictates the use of high doses and 
repeated administration of carnosine. Consequently, an important requisite that analogues of 
carnosine should posses in order to have therapeutic potential is a good degree of metabolic 
stability in human serum. For this reason, the NO-donor carnosine amides 7c-f were studied for 
their stability in this medium at 37°C. Unlike the lead, which is rapidly metabolized into its 
constituents following pseudo-first-order kinetics (t1/2 = 5 min), all products were stable over 3 h, 
similarly to the related des-NO amides 7a,b. This is in keeping with the lack of carboxylic group 
in their structures, which is essential to bind a Zn2+ ion present in the active cleft of the enzyme 
[33]. 
 
2.3. Dissociation constants (pKas) and lipophilicity determination 
Dissociation Constants (pKas) of 7a-f were determined by potentiometric titration; the results are 
reported in Table 1. As expected, all NO-donor derivatives and related des-NO analogues 
show pKa values that are very close either to that of the basic imidazole centre or of the amino 
group present on the lateral chain. At physiological pH (7.4) they exist prevalently as 
monocharged (92- 93%) and dicharged cations (5-6%). The apparent partition coefficient log D7.4 
of the products was evaluated by the shake-flask technique, using buffered water (pH 7.4)/n-
octanol as partition pair (Table 2). As expected, the introduction of nitrooxy function(s) on des-
NO amide scaffolds slightly increases the lipophilicity. 
 
2.4. Copper complexes 
Particular attention was paid to carnosine’s capacity to form complexes with Cu2+, in view of its 
role in protecting LDL against oxidation induced by Cu2+ ions [34,35]. Complex formation 
between copper (II) and nitrooxy substituted carnosine amides 7c-e was thus determined, 
following the same pH-metric technique used to study the parent des-NO analogue 7a. The study 
of 7f and of its des-NO analogue 7b was hindered by the low water solubility of the products in 
the experimental conditions. The stability constants of the complexes, expressed as 
βpqr=CupLqHr/CupLqHr for the reaction pCu + qL + rH = CupLqHr,, where L is the 
carnosine derivative, and p, q, r are the stoichiometric coefficients, the charges being omitted for 
simplicity. 
Since for ligands here studied the dissociation of both peptide and amide hydrogens takes place at 
too high pH values to allow a reliable evaluation of the relative pKH in aqueous solution, the 
concentration [L] in the expression of pqr takes into account only the hydrogen ion dissociation 
from protonated imidazole and amino nitrogens. If the presence of metal ion promotes further 
dissociation of hydrogen ion from peptide and amide group, in the above reaction the species H+ 
is subtracted and the index r becomes negative. So the r index is negative if the complex is formed 
by hydrogen ion dissociation from peptide and/or amide group. From the stability constants 
reported in Table 1, the ratio between free and total copper (II) concentrations can be calculated, 
assuming Cutotal= 2.5 x 10-6 and ligandtotal= 1 x 10-4 M. Analysis of the data shows that the NO-
donor carnosine amides display a good ability to sequester copper (II) ions, quite similar to those 
of the related des-NO analogues, even if their copper(II) complexes are weaker, because of the 
absence of carboxylate group, than that of carnosine. The capacities of the two diastereoisomers 
7d,e to sequester Cu2+ ions are similar. 
 
2.5. Biological activity 
2.5.1. Antioxidant activity 
Free transition-metal ions, especially iron and copper, play important roles in LDL peroxidation. 
In particular, copper ions at μM concentrations induce generation of free radicals at the low-
density lipoprotein (LDL) surface, with consequent oxidative modifications that are of paramount 
importance in the pathogenesis of a number of cardiovascular and neurodegenerative diseases 
[36- 39]. This oxidation can be prevented by using copper chelators, such as carnosine and related 
products. In previous research we assayed the ability of carnosine amides to control this 
oxidation, by evaluating Δlag time (Δtlag), namely the duration of the period prior to the onset of 
rapid peroxidation (propagation phase) compared to controls, and the propagation rate of the 
oxidation (R). Δtlag values were found to be dependent on the lipophilicity of the products, the 
most hydrophilic compounds being the most active (Figure 1b) [21]. Δlag time and R values of 
7c-f, evaluated under the same conditions used previously, are collected in Table 2. Δlag time 
values are slightly higher than those of the related des-NO reference compounds 7a,b and of 
carnosine, and closely fit the correlation reported in figure 1b, between measured log D7.4 and 
antioxidant activity of carnosine amide derivatives. R values are slightly lower than those of the 
reference compounds, and close to that of carnosine. The propagation rates of oxidation in the 
presence of the two diastereoisomers 7d,e are the same, but its onset is slightly faster for 7d. 
 
2.5.2. Vasodilator properties 
The ability of the target products to supply exogenous NO to blood vessels was evaluated by 
assessing their capacity to induce relaxation of endothelium-denuded rat-aorta strips, pre-
contracted with phenylephrine. All products were capable of relaxing the contracted tissue in a 
concentrationdependent manner. The vasodilator potencies of the products, expressed as EC50 
values, are reported in Table 2. They rank in order 7f>7e>7d>>7c. The vasorelaxant effect was 
cGMP-dependent, being blocked if experiments were carried out in the presence of 1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin- 1-one (ODQ), a well-known inhibitor of soluble guanylate 
cyclase (sGC). Interestingly, 7e is a vasodilator about three times more potent than its 
diastereoisomer 7d, indicating a possible role for the stereoisomery in the interaction of these 
compounds with the enzyme responsible for their NO production. 
 
2.5.3. HNE quenching activity 
As mentioned above, HNE is a particularly abundant reactive aldehyde, generated during lipidic 
peroxidation through β-cleavage of hydroperoxide derivatives of ω-6 polyunsaturated fatty acids. 
It is a potent bifunctional electrophile (Michael system and carbonyl group) able to interact with 
the nucleophile centres of DNA and proteins. After the first electrophile centre has reacted, the 
second centre undergoes further reaction, producing cross-linking of macromolecules. Carnosine 
is an efficient quencher of HNE, as well as of its amide derivatives. In order to evaluate the HNE 
trapping ability of products 7a-f, they were incubated in phosphate buffer, pH 7.4, with the 
aldehyde at 37 °C. HNE consumption over time was monitored by RP-HPLC [7]. The results 
obtained after 24 h are summarized in Table 2. The quenching effects on HNE fell in the range 
67.2-81.0%, the value for carnosine being 88.8 %. Among the two diastereoisomers, 7e is a 
slightly stronger quencher than 7d. 
 
2.5.4. Cerebral ischemia-reperfusion injury 
Reduced blood supply to an organ induces organ injury, whose severity depends on the degree 
and duration of blood-flow reduction. Reperfusion of ischemic tissue results in further injury. The 
molecular mechanisms which underlie I/R injury are complex and not fully understood.  
It is certain that overproduction of reactive oxygen metabolites during reperfusion, in particular of 
the superoxide anion (O2 -.), plays a central role. Hydrogen peroxide (H2O2) is formed from this 
radical by action of superoxide dismutase (SOD). H2O2 is a source, through the Haber-Weiss 
reaction, of the highly-toxic hydroxyl radical (OH.), the principal agent responsible for the cell 
damage induced by oxidative stress. Release of pro-inflammatory cytokines, increased expression 
of endothelial adhesion molecules and of chemotactic factors, as well as infiltration of leukocytes, 
also play important roles in post-ischemic inflammation, contributing to progression of tissue 
damage [40]. Several studies have clearly demonstrated that carnosine exerts beneficial effects 
against I/R-induced organ damage, including the brain [41-43]. However, its rapid and complete 
enzymatic hydrolysis by carnosinases severely limits its potential therapeutic use. The role of NO 
in I/R is complex. It exerts either protective or toxic effects, depending on the level, location, 
source, and environment [44,45]. Beneficial effects in I/R are due to its numerous capabilities: it 
relaxes vascular smooth muscle, protects the microvasculature, prevents neutrophile infiltration, 
maintains vascular permeability, modulates cytokine expression, as well as displaying 
antioxidant, anti platelet-activating factor, and antimicrobial properties. Consequently, a supply of 
exogenous NO (NO-donors) might have beneficial effects in acute ischemic damage [46,47]. In 
order to reinforce experimental evidence of the therapeutic potential of the NO-donor carnosine 
amides described here, the most promising derivative (compound 7e), its des-NO analogue 7a, 
and carnosine (1) were tested in a well-known in vivo model of cerebral I/R injury, as we report 
elsewhere [48]. In comparison with brain sections obtained from sham-operated rats, those rats 
that underwent cerebral I/R injury showed an infarct volume of 31.6 ± 4.1% of the total brain. As 
shown in Figure 2, compound 1 administration (1 g/kg) almost halved the I/R-induced infarct 
volume. Our results are consistent with previous studies showing that exogenously administered 
carnosine evoked a marked reduction in infarct size when administered before the ischemic injury 
either in adult and neonatal rat models [49-51]. Carnosine has been reported to exert protective 
effects on neurological symptoms and animal mortality even when injected into the blood stream 
after the ischemic event [52]. Here for the first time we show that a marked reduction in the mean 
size of the ischemic area was also measured when two carnosinase-stable derivatives, compound 
7e and its des-NO analogue 7a, were administered at 500 mg/kg, without any significant 
difference among groups. These results demonstrate that both of these carnosine derivatives exert 
protective effects against I/R injury, at lower doses than is required for carnosine, being about 
four time more active than the lead (1). In our acute experimental model, the potential further 
beneficial effect of NO release by compound 7e was blunted by the predominant role of 
antioxidant activity due to the carnosine amide substructure. 
This observation is in keeping with previous in vivo and in vitro studies reporting that carnosine 
neuroprotective effects were almost entirely attributable to its ability to inhibit and/or prevent 
oxidative and nitrosative stress [13]. However, recently, carnosine has also been demonstrated to 
reduce glutamate excitotoxicity through the regulation of the glutamate transporter-1 [50], to 
protect the bioelectric activity of nervous cells by restoring the activity of the glutamatergic and 
GABAergic receptors [53] and to affect the apoptotic cascade in the ischemic brain by inhibiting 
mRNA expression of apoptosis-inducing factor and caspase-3 [51]. Here we show that the NO-
donor carnosine derivative 7e may modulate cytokine production in the ischemic brain. In fact, 
when serum tumor necrosis factor (TNF)-concentrations were measured, as typical marker of 
the excessive inflammatory response associated with I/R injury (Figure 3), the two-fold increase 
in TNF-levels evoked by I/R was significantly reduced by administering compound 7e; in 
contrast, both des-NO analogue 7a and carnosine had no effect on TNF-production. TNF-is 
one of the key immunomodulatory and pro-inflammatory cytokines, which has been clearly 
demonstrated to be up-regulated during cerebral I/R injury [54]. Recent evidence also suggests 
that chronic exposure to high levels of TNF-may induce changes in both lipid and glucose 
metabolism, likely to exert pro-atherogenic effects, thus promoting the development of 
atherosclerotic lesions [55]. Therefore, although decreased cytokine production is not essential for 
protection against acute cerebral injury, it is possible that the decreased cytokine production 
evoked by compound 7e might significantly contribute to the potential protective effects of its 
prolonged administration in vascular disorders characterized by high levels of chronic 
inflammation, such as I/R-induced organ damage, atherosclerosis and Alzheimer’s disease. 
 
3. Conclusions 
In conclusion, we have designed and realized a new series of carnosine amide derivatives with 
NO-donor properties. The results of this study demonstrate that our compounds are a new class of 
NO-donor antioxidants endowed with HNE scavenging and Cu2+ chelating properties, able to 
inhibit LDL oxidation. Preliminary pharmacological characterization of 7e shows that these 
compounds are worthy of additional study as potential tools in the treatment of complex vascular 
and neurodegenerative disorders, whose onset and progression involve oxidative stress and 
decreased NO availability. 
 
4. Experimental 
4.1. Instrumentation and chemicals 
Determination of melting points of final compounds (7b-f) was affected by their complex thermal 
behaviour; consequently, melting points are not reported here. 1H and 13C NMR spectra were 
obtained on a Bruker Avance 300, at 300 and 75 MHz, respectively, or on a Bruker AC-200, at 
200 and 50 MHz, respectively; in ppm rel. to SiMe4 as the internal standard; coupling constants 
J in Hz. 13C NMR spectra were fully decoupled. The following abbreviations are used: s: singlet, 
d: doublet, dd: doublet doublet, t: triplet, qt: quartet, m: multiplet, br: broad, Im: imidazole ring. 
Mass spectra were recorded on a Finnigan-Mat TSQ-700. Flash chromatography (FC) was 
performed on BDH silica gel (particle size 40-63 μm). When not otherwise specified, anhydrous 
magnesium sulphate (MgSO4) was used as drying agent for organic phases. Analysis (C, H, N) of 
the target compounds was performed by Service de Microanalyse, Université de Genève, Genève 
(CH), and the results were within 0.4% of theoretical values. Derivatives 7a [21], 3c [29], 11 
[30], and 12 [31] were synthesised by the methods reported. HNE (4-hydroxy-trans-2,3-nonenal) 




4.2.1. General procedure for the synthesis of derivatives 7b-f 
To a stirred solution of Fmoc-His-(Trt)-OH (2) (2.5 g; 4 mmol) in dry DMF (40 mL), DIPEA 
(1.03 mL; 6 mmol), HBTU (2.29 g; 6 mmol) and HOBt (0.08 g; 0.6 mmol) were added. After 10 
min, the appropriate amine 3b-f (6 mmol) was added; the reaction mixture was stirred at RT until 
TLC evidenced complete consumption of starting material (1-18 h). The solvent was removed 
under reduced pressure (oil pump) and the residue taken up with CH2Cl2 (40 mL) and washed 
with water (3 x 30 mL), brine (30 mL), then dried and evaporated under reduced pressure. The 
residual oil was purified by flash chromatography, eluting with CH2Cl2/MeOH 9.9/0.1 to 9.5/0.5 
to afford the desired intermediate 4b-f (57-94%). To a stirred solution of the resulting 
intermediate (2.59 mmol) in dry DMF (23 mL), piperidine (1.15 mL; 11.6 mmol) was added and 
the reaction mixture stirred at RT for 1 h. The solvent was evaporated under reduced pressure and 
the solid residue was taken up with CH2Cl2 (30 mL) and washed with water (3 x 30 mL) and brine 
(30 mL). The organic phase was dried (Na2SO4) and the crude product was purified by flash 
chromatography, eluting with CH2Cl2/MeOH 9.8/0.2 to 8/2 to yield the desired intermediates 5b-f 
(74-100%). To a stirred solution of the free amines 5b-f (1.75 mmol) and Boc-β-Ala-OH (0.35 g; 
1.83 mmol) in dry CH2Cl2 (30 mL) kept at 0 °C, DCC (0.36 g; 1.75 mmol) was added; the ice 
bath was removed and the reaction was stirred at RT for 2-18 h. The reaction mixture was cooled 
to 0 °C. The precipitate was filtered and washed with cold (0 °C) CH2Cl2. The liquid phase was 
washed with water (3 x 30 mL), brine (30 mL), then dried and evaporated under reduced pressure 
to leave a white solid. The crude material was purified by flash chromatography, eluting with 
CH2Cl2/MeOH 9.8/0.2 to 9.5/0.5 to give the desired derivatives 6b-f (59-91%) as white foams. 
The resulting products were dissolved in CH2Cl2 (21 mL), treated with CF3COOH (2.1 mL) and 
stirred at RT for 20 h. The solvent was evaporated under reduced pressure and the semisolid 
residue was treated with water (30 mL). The precipitate formed was filtered off through a sintered 
glass funnel, the water phase was washed with CH2Cl2 (2 x 20 mL), then with EtOAc (2 x 20 mL) 
and evaporated to afford the final products 7b-f. 
 
4.2.1.1. β-alanyl-N-[4-(propyloxy)benzyl]-L-histidinamide ditrifluoroacetate (7b) 
The product was recrystallized twice from dry MeOH/Et2O and freeze-dried to yield 7b as a white 
foam (67%). 1H-NMR (CD3OD): δ, 8.71 (s, 1H, ImH2); 7.24 (s, 1H, ImH5); 7.13 (d, 2H, J=8.4 
Hz, ArH2’,6’); 6.84 (d, 2H, J=8.4 Hz, ArH3’,5’); 4.70 (m, 1H, CH); 4.30-4.23 (m, 2H, NHCH2); 
3.90 (t, 2H, J=6.3 Hz, OCH2); 3.22-3.08 (m, 4H, ImCH2, CH2NH3 +); 2.68-2.62 (m, 2H, COCH2); 
1.80-1.73 (m, 2H, CH2CH2CH3); 1.03 (t, 3H, J=7.2 Hz, CH3). 13C-NMR (CD3OD): δ, 172.4; 
171.9; 160; 135; 131.5; 131.2; 130; 118.4; 115.5; 70.6; 53.8; 43.7; 36.8; 32.7; 28.3; 23.7; 10.8. 
Anal.Calc. for 14 C19H27N5O3 • 2 CF3COOH • H2O, C% 44.59, H% 5.04, N% 11.30. Found: C% 
44.60, H% 4.98, N% 11.42. 
 
4.2.1.2. β-alanyl-N-[3-(nitrooxy)propyl]-L-histidinamide ditrifluoroacetate (7c) 
The product was recrystallized from dry MeOH/Et2O and freeze-dried to yield 7c as a white foam 
(89%). 1H-NMR (CD3OD): δ, 8.81 (s, 1H, ImH2); 7.35 (s, 1H, ImH5); 4.64 (m, 1H, CH); 4.48 (t, 
2H, J = 6.3 Hz, CH2ONO2); 3.31-3.10 (m, 6H, ImCH2, CH2NH3 +, CH2NH); 2.68-2.65 (m, 2H, 
COCH2); 1.92-1.88 (m, 2H, CH2CH2CH2). 13C-NMR (CD3OD): δ, 172.44; 172.41; 135.1; 131.2; 
118.4; 72.3; 53.9; 37.1; 36.8; 32.7; 28.0; 27.8. Anal. Calc. for: C12H20N6O5 • 2 CF3COOH • H2O, 
C% 33.46, H% 4.21, N% 14.63; Found C% 33.83, H% 4.14, N% 14.40. 
 
4.2.1.3. β-alanyl-N-[(2S)-2,3-bis(nitrooxy)propyl]-L-histidinamide ditrifluoroacetate (7d) 
The product was recrystallized twice from dry MeOH/Et2O and freeze-dried to yield 7d as a white 
foam (70%). 1H-NMR (CD3OD): δ, 8.73 (s, 1H, ImH2); 7.33 (s, 1H, ImH5); 5.45 (m, 1H, 
CHONO2); 4.88-4.58 (m, 3H, CHNH, CH2ONO2); 3.61-3.41 (m, 2H, NHCH2); 3.30-3.06 (m, 4H, 
ImCH2, CH2NH3 +); 2.86-2.73 (m, 2H, COCH2). 13C-NMR (CD3OD): δ, 173.1; 172.5; 133.5; 
131.2; 118.4; 79.2; 71.2; 54; 39.1; 36.8; 32.6; 27.8. Anal. Calc. for: C12H19N7O8 • 2 CF3COOH 
C% 31.13, H% 3.43, N% 15.,88. Found: C% 31.02, H% 3.61, N% 15.94. 
 
4.2.1.4. β-alanyl-N-[(2R)-2,3-bis(nitrooxy)propyl]-L-histidinamide ditrifluoroacetate (7e) 
The product was recrystallized twice from dry MeOH/Et2O and freeze-dried to yield 7e as a white 
foam (63%). 1H-NMR (CD3OD): δ, 8.73 (s, 1H, ImH2); 7.34 (s, 1H, ImH5); 5.52-5.47 (m, 1H, 
CHONO2); 4.91-4.86 (m, 1H, CHNH); 4.68-4.59 (m, 2H, CH2ONO2); 3.74-3.68 (m, 2H, 
NHCH2); 3.31-3.07 (m, 4H, ImCH2, CH2NH3 +); 2.7-2.64 (m, 2H, COCH2). 13C-NMR (CD3OD): 
δ, 173.1; 172.6; 135.2; 131.2; 118.4; 79.2; 71.3; 54; 39.2; 36.9; 32.6; 27.8. Anal. Calc. for 
C12H19N7O8 • 2 CF3COOH C% 31.13, H% 3.43, N% 15.88. Found: C% 30.91, H% 3.61, N% 
15.97.  
 
4.2.1.5. β-alanyl-N-{4-[3-(nitrooxy)propyloxy]benzyl}-L-histidinamide ditrifluoroacetate (7f) 
The product was recrystallized twice from dry MeOH/Et2O and freeze-dried to yield 7f as a white 
foam (42%). 1H-NMR (CD3OD): δ, 8.64 (s, 1H, ImH2); 7.23 (s, 1H, ImH5); 7.16 (d, 2H, J=8.4 
Hz, ArH2’,6’); 6.87 (d, 2H, J=8.4 Hz, ArH3’,5’); 4.73-4.65 (m, 3H, CH, CH2ONO2); 4.35-4.23 
(m, 2H, NHCH2); 4.06 (t, 2H, J=6 Hz, OCH2); 3.27-3.05 (m, 4H, ImCH2, CH2NH3 
+); 2.72-2.60 (m, 2H, COCH2); 2.22-2.14 (m, 2H, CH2CH2CH2). 13C-NMR (CD3OD): δ, 172.3; 
172; 159.4; 135.2; 132; 131.6; 130.1; 118.3; 115.6; 71.6; 65.2; 54; 43.7; 36.9; 32.7; 28.6; 28.1. 
Anal.Calc. for C19H26N6O6 • 2 CF3COOH • 2 H2O, C% 39.55, H% 4.62, N% 12.03. Found: C% 
39.19, H% 4.27, N% 12.08. 
 
4.2.1.6. 4-propoxybenzenemethanamine (3b). 
In a flame-dried flask, NaH 60 % in mineral oil (0.80 g; 20.1 mmol) was suspended in dry DMF 
(20 mL), then p-hydroxybenzonitrile (8) (2.00 g; 16.8 mmol) was added portionwise and the 
mixture was stirred for 1 h at RT. After this time, a solution of bromopropane (4.13 g; 33.6 mmol) 
in dry DMF (10 mL) was added and the reaction stirred for a further 3 h. The mixture was diluted 
with CH2Cl2 (150 mL), washed with water (3 x 100 mL), dried (Na2SO4) and evaporated to afford 
the desired alkylated intermediate, which was dissolved in dry Et2O (40 mL) and added dropwise 
during 30 min to a stirred suspension of LiAlH4 (0.95 g; 25.1mmol) in dry Et2O (60 mL). When 
addition was complete, the mixture was refluxed for 30 min, then cooled (0 °C) and cautiously 
treated with water (10 mL) and CH2Cl2 (80 mL), the precipitate formed was filtered through a 
sintered funnel and the resulting mixture was washed with brine (3 x 40 mL), dried, and 
evaporated to afford 3b (2.65 g; 87 %) as a pale yellow oil. The product was used immediately in 
the next step without further purification. 
 
4.2.1.7. (2S) 2,3 (dinitrooxy)propan-1-ammonium nitrate (3d) 
In a flame-dried flask equipped with a CaCl2 guard tube and an air condenser, (R)-3-amino-1,2- 
propandiol (1.17 g; 12.8 mmol) was suspended in dry CH2Cl2 (34 mL) and kept at 0 °C. Fuming 
HNO3 (d= 1.52 g/mL) (3.30 mL) was added cautiously and the mixture stirred vigorously at 0 °C 
for 2.5 h. Acetic anhydride was slowly added and after 1 h the precipitate was filtered through a 
sintered glass funnel, collected and dried over P2O5, KOH overnight, to afford 2.65 g (85 %) of an 
off-white solid. The product was recrystallized from iPrOH to obtain a white solid. 1H-NMR 
(DMSO-d6): δ, 8.15 (s, br 3H, NH3 +); 5.68-5.61 (m, 1H, CHONO2); 4.98 (dd, 2H, Jgem = 12.9 Hz; 
Jvic = 3.3 Hz, CHHONO2); 4.79 (dd, 2H, Jgem = 12.9; Jvic = 5.4 Hz, CHHONO2); 3.38 (dd, 2H, Jgem 
= 14.1; Jvic = 3.3 Hz, CHHNH3 +); 3.21 (dd, 2H, Jgem = 14.1; Jvic = 9.3 Hz, CHHNH3 
+). 13C-NMR (DMSO-d6): δ, 76.4; 70; 37.3, spectral data are in agreement with those of an 
authentic sample [56]  
 
4.2.1.8. (2R) 2,3 (dinitrooxy)propan-1-ammonium nitrate (3e) 
In a flame-dried flask equipped with a CaCl2 guard tube and an air condenser, kept at 0 °C, dry 
CH2Cl2 (34 mL) and fuming HNO3 (d= 1.52) (3.30 mL) were mixed cautiously; to this mixture, 
powdered (R)-3-amino-1,2-propandiol (1.2 g; 13.2 mmol) was added portionwise. The mixture 
was stirred vigorously at 0 °C for 2 h, then acetic anhydride (3.0 mL; 31.8 mmol) was added and 
the reaction stirred at 0 °C for a further 45 min The resulting precipitate was filtered through a 
sintered glass funnel, collected and dried over P2O5, KOH overnight, to afford 2.60 g (81 %) of an 
off-white solid. The product was recrystallized from iPrOH to obtain a white solid. 1H-NMR 
(DMSO-d6): δ, 8.16 (s, br 3H, NH3 +); 5.67-5.62 (m, 1H, CHONO2); 4.98 (dd, 2H, Jgem = 12.9 Hz; 
Jvic = 3.3 Hz, CHHONO2); 4.79 (dd, 2H, Jgem = 12.9; Jvic = 5.4 Hz, CHHONO2); 3.39-3.33 (m, 2H, 
CHHNH3 +); 3.21 (dd, 2H, Jgem = 14.1; Jvic = 9.3 Hz, CHHNH3 +). 13C-NMR (DMSO-d6): δ, 76.4; 
70; 37.3, spectral data are in agreement with those of an authentic sample [57]. 
 
4.2.1.9. 3-[4-(aminomethyl)phenoxy]propyl nitrate (3f) 
To a stirred solution of 12 (1.7 g; 5.84 mmol) in dry THF (40 mL) potassium tert-butoxide was 
added, and after 15 min 11 (1.37 g; 6.13 mmol) in dry THF (15 mL) was slowly added. The 
reaction mixture was stirred at 60 °C for 3 h, cooled and cautiously treated with water (30 mL). 
The aqueous layer was extracted with CH2Cl2 (3 x 30 mL), dried (MgSO4) and evaporated under 
reduced pressure to afford the expected intermediate as a yellow oil. This oil was dissolved in 
CH2Cl2 (60 mL) and CF3COOH (4.25 mL) and stirred for 2 h. The solvent was evaporated and the 
residue taken up with 5 % aqueous NaHCO3, extracted with CH2Cl2 (3 x 20 mL) and dried 
(Na2SO4) to leave a orange coloured oil which was purified by flash chromatography, eluting with 
CH2Cl2/MeOH 9.9/0.1 gradient to CH2Cl2/MeOH 8/2 to afford the title product in quantitative 
yield as colourless oil. 1H-NMR (CDCl3): δ, 7.23 (d, 2H, J=8.5 Hz, 2 ArH2’,6’); 6.84 (d, 2H, 
J=8.5 Hz, 2 ArH3’,5’); 4.66 (t, 2H, J=6.3 Hz, CH2ONO2); 4.04 (t, 2H, J=5.8, OCH2); 3.79 (m, 
2H, CH2NH2); 2.24-2.15 (m, 4H, CH2; NH2). 13C-NMR (CDCl3): δ, 157.5; 135.2; 128.5; 114.5; 
70; 63.6; 45.8; 27. MS CI (isobutane) (m/z): 227 [MH+]. 
 
4.3. Determination of dissociation constants and lipophilicity descriptor 
The ionisation constants of the compounds were determined by potentiometric titration with the 
GLpKa apparatus (Sirius Analytical Instruments Ltd, Forest Row, East Sussex, UK). Ionisation 
constants of carnosine 1 and compounds 7a-f were obtained by aqueous titration, with at least 
four separate titrations for each compound: different aqueous solutions (ionic strength adjusted to 
0.15 M with KCl) of the compounds (20 mL, about 1 mM) were initially acidified to pH 1.8 with 
0.5 N HCl; the solutions were then titrated with standardized 0.5 N KOH to pH 12.2. 
Calculated partition coefficients (clog D7.4) were obtained from CLOGP (CLOGP for windows, 
version 4.0, BioByte Corp. Claremont, CA, USA) according to the equation: clog D7.4 = CLOGP - 
log [1+10(pKa2-pH)+10(pKa2-pKa1-2pH)]. 
The apparent partition coefficients log D7.4 were obtained by the shake-flask procedure at pH 7.4 
(phosphate buffer solutions with ionic strength adjusted to 0.15 M with KCl); n-octanol was 
added to the buffers and the two phases were mutually saturated by shaking for 4 h. The 
compounds were solubilised in the buffered aqueous phase at a concentration of about 0.1 mM 
and an appropriate amount of n-octanol was added. The two phases were shaken for about 20 
min, by which time the partitioning equilibrium of solutes was reached, and then centrifuged 
(10,000 rpm,10 min). The concentration of solute in the aqueous phase was measured by UV 
spectrophotometry(UV-2501PC, Shimadzu) at 230 nm. For each compound, at least 6 log D 
values were measured. 
 
4.4. Copper Complexes 
Complex formation, between copper(II) and carnosine (1) and derivatives 7a-f, was investigated 
by means of the classical pH-metric technique with the GLpKa apparatus. For each compound, at 
least three separate titrations were performed: different aqueous solutions of the compounds and 
of CuCl2 equimolar (1 mM) were initially acidified to pH 1.8 with 0.5 N HCl; the solutions were 
then titrated with standardized 0.5 N KOH to pH 12.2. The measurements were made under 
nitrogen at 25.0 ± 0.1 °C and ionic strength adjusted to 0.15 M (KCl). Elaboration of 
experimental pH-metric data, to calculate the values of formation constants, was done using the 
BSTAC software [58]. 
 
4.5. Stability in human serum 
A solution of each compound (10 mM) in water was added to human serum (Sigma) preheated to 
37 °C; the final concentration of the compound was 0.5 mM. The solutions were incubated at 37 
0.5 °C and, at appropriate time intervals, 500 L of reaction mixture were withdrawn and added 
to 500 L of acetonitrile containing 0.1% trifluoroacetic acid, in order to deproteinize the serum. 
The sample was sonicated, vortexed and then centrifuged for 10 min at 2150 g. The clear 
supernatant was filtered through 0.45 m PTFE filters (Alltech, Deerfield, IL, USA) and analysed 
by RP-HPLC. HPLC analyses were performed with a HP 1100 chromatograph system (Agilent 
Technologies, Palo Alto, CA, USA) equipped with a quaternary pump (model G1311A), 
membrane degasser (G1379A), diode-array detector (DAD) (model G1315B) integrated in the 
HP1100 system. Data analysis was done using a HP ChemStation system (Agilent Technologies, 
Palo Alto, CA, USA). The analytical column was a Purospher C18-endcapped (250 × 4.6 mm, 5 
μm particle size) (Merck Darmstadt, Germany). The mobile phase consisting of methanol/20 mM 
CH3COONa pH 4.5 - 5 mM SDS (80/20 to 60/40 in accordance with the polarity of the 
compound) and the flow-rate was 0.7 mL/min. The injection volume was 20 L (Rheodyne, 
Cotati, CA). The column effluent was monitored at 210 and 223 nm, referenced against a 360 nm 
wavelength. 
 
4.6. Biological activity 
4.6.1. LDL isolation and oxidation 
Human plasma from healthy donors was provided by the Blood Bank (A.O. San Giovanni Battista 
Turin) and fortified with 0.1% EDTA. The LDL fraction was isolated by ultracentrifugation 
through NaCl discontinuous gradients, and collected as the fraction floating at a density of 1.019- 
1.063 g/mL. The lag phase (tlag) and propagation rate (R) were determined as described elsewhere 
[59]. EDTA was removed by rapid filtration through disposable desalting columns Econo-Pac 10 
DG (Bio-Rad). Filtered LDL aliquots were diluted with PBS (10 mM phosphate buffer, pH 7.4) to 
give a final concentration of 50 μg LDL protein/mL, and transferred to a 1-cm cuvette, either with 
50 μL of water alone, or with 50 μL of the test compound solution in water at a final 
concentration of 100 μM. Formation of conjugated dienes was measured spectrophotometrically 
in a Varian Cary 50 Bio spectrophotometer, equipped with a thermostatic control (37 °C) and an 
automatically exchangeable multi-position cuvette holder, operating at 234 nm. Oxidation was 
initiated by adding to the LDL a suspension of CuSO4 at a final concentration of 2.5 μM. 
 
4.6.2. HNE scavenging studies 
HNE (final concentration 50 μM in 1 mM phosphate buffer, pH 7.4) was incubated with a 
solution of compounds 7a-f, or with carnosine (1) (final concentration 1 mM in 1 mM phosphate 
buffer, pH 7.4) for different periods (up to 24 h) at 37 °C. Samples for each different incubation 
time were analyzed directly by HPLC to measure HNE consumption, as described elsewhere [7]. 
HNE was determined by reverse-phase HPLC, using a HP 1100 chromatograph system (Agilent 
Technologies, Palo Alto, CA, USA) previously described. Reaction mixture (20 μL) was eluted 
on a Agilent Zorbax Eclipse XDB-C18 column (150 x 4.6 mm; particle size 5 μm). The mobile 
phase was 60% A (water/acetonitrile/formic acid; 9:1:0.01, v/v/v) and 40% B (water/acetonitrile; 
1:9, v/v) delivered at a flow-rate of 1 mL/min. The column effluent was monitored at 223 nm. 
 
4.6.3. Vasodilator activity assay. 
Thoracic aortas were isolated from male Wistar rats weighing 180-200 g. The endothelium was 
removed and the vessels were cut helically: three strips were obtained from each aorta. The strips 
were mounted in organ baths containing 30 mL of Krebs-bicarbonate buffer of the following 
composition (mM): NaCl 111.2, KCl 5.0, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.0, NaHCO3 12, 
glucose 11.1 maintained at 37 °C and continuously gassed with 95% O2-5% CO2 (pH=7.4). The 
aortic strips were allowed to equilibrate for 90 min and then contracted with 1 M L-
phenylephrine. When the response to the agonist reached a plateau, cumulative concentration–
response curves were determined. The effect of 1 M ODQ was evaluated in a separate series of 
experiments, in which the inhibitor of sGC was added 5 min before contraction. EC50 values are 
the mean of at least 5 determinations. Responses were recorded by an isometric transducer 
connected to the MacLab System PowerLab. 
 
4.7. In vivo experimental protocols 
4.7.1. Animals and surgery. 
Male Wistar rats (Harlan-Italy; Udine, Italy) weighing 210 to 230 g were housed in a controlled 
environment at 252 °C with alternating 12-h light and dark cycles. They were provided with a 
Piccioni pellet diet (n.48, Gessate Milanese, Italy) and water ad libitum. All rats were 
acclimatized in our animal facility for at least 1 week prior to experiments, and stressful stimuli 
were avoided. 
Animal care was in compliance with Italian regulations on the protection of animals used for 
experimental and other scientific purposes (D.M. 116/92) as well as with the Guide for the Care 
and Use of Laboratory Animals, as adopted and promulgated by the U.S. National Institutes of 
Health. The experimental protocol, approved by the Turin University Ethics Committee, was 
performed as described elsewhere [48]. Briefly, rats were anaesthetised with i.p. injection (30 
mg/kg) of Zoletil 100 (mixture of tiletamine and zolazepam, Laboratoires Virbac, France), which 
was supplemented as needed. Anaesthetised rats were placed onto a thermostatically controlled 
heating pad, a rectal temperature probe was inserted and body temperature was monitored and 
maintained at 37 C. Both common carotid arteries were exposed over a midline incision and a 
dissection was made between the sternocleidomastoid and the sternohyoid muscles, parallel to the 
trachea. Each carotid artery was freed from its adventitial sheath and vagus nerve, which was 
carefully separated and maintained. Ischemia was achieved by clamping the bilateral common 
carotid arteries for 30 min, using non-traumatic artery clamps (Micro Bulldog Clamps, Harvard 
Apparatus Ltd., Kent, U.K.). 
During ischemia, the animals were monitored for body temperature, respiration pattern, loss of 
righting reflex, unresponsiveness, corneal reflexes, and fixed and dilated pupils. Recirculation of 
blood flow was established by releasing the clips, and restoration of blood flow in the carotid 
arteries was confirmed by careful observation. Reperfusion was allowed for 24 h. Post-surgery, 
the animals were kept for at least 3 h in a 37 C incubator to ensure that postoperative recovery 
was satisfactory. Thereafter, they were group-housed under temperature- and light-controlled 
conditions, with food and water ad libitum. At the end of the reperfusion period, the rats were 
anaesthetised and killed by decapitation, after aortic exsanguination; the forebrain was rapidly 
dissected at 0 C. Sham-operated rats underwent identical surgical procedures, except that no 
artery clamps were applied. 
 
4.7.2. Drug treatments. 
Animals were randomly allocated into different groups (n = 5 per group): Sham (the common 
carotid arteries were exposed but not occluded); I/R group; carnosine group (the drug was 
administered at 1 g/kg); compound 7e group (the drug was administered at 500 mg/kg) and des-
NO analogue 7a group (the drug was administered at 500 mg/kg). All compounds were prepared 
in 5% DMSO and injected i.v., at the beginning of reperfusion and again after 6 h. For all 
experiments, concentrations of drugs were calculated such that all animals received equal 
volumes of DMSO. 
The dose of carnosine used was based on that previously shown to attenuate injury in animal 
models of cerebral I/R injury [49]. 
 
4.7.3 Determination of infarct volume. 
After 24 h of reperfusion, the rats were killed with an overdose of Zoletil 100 (mixture of 
tiletamine and zolazepam) and decapitated. The rats’ brains were immediately removed and 
placed in ice-cold saline for 5 min. Each brain was then placed in a brain matrix and coronal 
sections were cut into 2- mm slices. Brain slices were immediately immersed in 2% 2,3,5-
triphenyltetrazolium chloride monohydrate (TTC) solution (in saline) at 37 °C for 30 min, 
followed by 4% paraformaldehyde solution. The infarct area and hemisphere area of each section 
were traced and quantitated by a computerized image analysis system (Inquiry; Loats, 
Westminster, MD, U.S.A.) and the infarct area was expressed as a percentage of the whole brain 
area. 
 
4.7.4. Determination of serum tumour necrosis factor (TNF)-concentration. 
TNF-serum concentrations were measured using commercial enzyme-linked immunosorbent 
assay (ELISA) kits (Cayman Chemical, Ann Arbor, MI), following the protocol provided by the 
manufacturer; results are expressed as pg/mL. 
 
4.7.5. Statistical analysis. 
All values in both the text and figures are expressed as means standard error of the mean 
(S.E.M.) for n observations. One-way analysis of variance with Dunnett's post test was performed 
using GraphPad Prism version 4.02 for Windows (GraphPad Software, San Diego, California, 
USA) and p values below 0.05 were considered to be significant. 
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Scheme 1. Preparation of derivatives 7a-f. Reagents and conditions: (a) DIPEA, HBTU, HOBtcat, 
10 min RT, then 3a-f 1-18 h, RT (57-94 %); b) Piperidine , dry DMF, 1 h, RT. (74-100 %); c) 
Boc--Ala(OH), DCC, dry CH2Cl2, 0 °C to RT. 2-18 h. (59-91 %); d) CF3COOH 10 % in 





Scheme 2. Preparation of intermediate amines 3b, 3d-f. Reagents and conditions: (a) NaH, RT, 
dryDMF, 1h, then 3-Bromopropane, RT, 3 h; (b) LiAlH4, dry Et2O, RT to reflux, 30 min; (c) 
fumingHNO3, 0 °C, dry CH2Cl2, 2 h, then Ac2O, 0 °C, 1 h; (d) Tert-BuOK, THF dry, RT, 15 min 
then reflux 3 h; (e) CF3COOH 10 % in CH2Cl2, 2 h , RT. 
 
Figure 1. a) Relationship between antioxidant activity (expressed as Δtlag) and calculated 
lipophilicity (clog D7.4oct) obtained for carnosine amide derivatives (○) [21] and for new 
compound7b (●). Calculated clog D7.4oct for designed NO-donor analogues 7c-f (▲) is also 
reported. b)Relationship between antioxidant activity (expressed as Δtlag) and measured 
lipophilicity (logD7.4oct) obtained for all carnosine amide derivatives: (○) compounds described in 





Figure 2. Effects of carnosine derivatives on infarct volume induced by cerebral I/R injury. 
Effects evoked by the administration of carnosine (1) (1 g/kg), compound 7e (500 mg/kg) or its 
des-NO analogue 7a (500 mg/kg) on cerebral infarct volume were evaluated at 24 h reperfusion. 







Figure 3. Alterations in serum levels of TNF-α induced by compound 7e. Rats were subjected to 
30min ischemia and 24 h reperfusion (I/R). Carnosine (1) (1 g/kg), compound 7e (500 mg/kg) or 
its des-NO analogue 7a (500 mg/kg) were administered during reperfusion. Data are means 
S.E.M. of five animals per group. ● p < 0.05 versus 7e. 
 
 
 
